Therapeutic group for women on the autism spectrum

A randomised controlled trial: A trans-diagnostic theory based therapeutic group for women on the autism spectrum investigating the impact and management of a diagnosis of an autism spectrum condition given in adulthood

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13900653

Enrollment

Registered

2017-01-10

Start date

2016-11-11

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metal health and autism spectrum conditions Mental and Behavioural Disorders Metal health and autism spectrum conditions

Interventions

Participants are randomised to one of two groups using a computer-based system. Intervention group: A pilot trans-diagnostic group-based intervention encompassing CBT and mindfulness-based therapy o

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Female 2. With a diagnosis of Autism Spectrum Condition 3. Aged 18-65 years 4. Any racial and cultural background and any religious belief or sexuality

Exclusion criteria

Exclusion criteria: 1. Men 2. Those without ASD diagnosis 3. Those not referred to Psicon 4. Those that present 'at risk' after initial risk assessment

Design outcomes

Primary

Measure	Time frame
1. Anxiety will be measured using the Generalised Anxiety Disorder 7-item scale (GAD-7) at baseline and 6 weeks 2. Depression and low mood will be measured using the Patient Health Questionnaire 9-item (PHQ-9) at baseline and 6 weeks 3. Self-esteem will be measured using the Rosenberg Self-Esteem Scale at baseline and 6 weeks 4. Any trauma will be measured using the Impact of Events Scale - Revised at baseline and 6 weeks	—

Measure

Time frame

1. Anxiety will be measured using the Generalised Anxiety Disorder 7-item scale (GAD-7) at baseline and 6 weeks 2. Depression and low mood will be measured using the Patient Health Questionnaire 9-item (PHQ-9) at baseline and 6 weeks 3. Self-esteem will be measured using the Rosenberg Self-Esteem Scale at baseline and 6 weeks 4. Any trauma will be measured using the Impact of Events Scale - Revised at baseline and 6 weeks

—

Secondary

Measure	Time frame
General quality of life and experienced strengths and difficulties will be measured using the CORE-10, World Health Organisation Quality of Life Scale and Strengths and Difficulties Questionnaire at baseline and 6 weeks.	—

Countries

United Kingdom

Contacts

Public ContactLucy Elias

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026